Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease: a Pivotal, Sham-controlled, Randomized, Double-blind, Multicentric Investigation (LIGHT4LIFE)

NCT05926011 is registered in ClinicalTrials.gov with REGEnLIFE SAS as lead sponsor.

NCT NCT05926011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05926011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of RGn600 in Patients With Mild-to-moderate Alzheimer's Disease: a Pivotal, Sham-controlled, Randomized, Double-blind, Multicentric Investigation (LIGHT4LIFE)
Lead sponsor
REGEnLIFE SAS
Phase
Not applicable
Overall status
Recruiting
Start date
July 24, 2023
Completion date
December 31, 2027
Enrollment
108 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease